New Delhi: AbbVie Inc said on Wednesday it had halted enrollment for a late-stage trial of Rova-T as a second-line therapy for advanced small-cell lung cancer, following recommendations made by an independent data monitoring committee.
The committee’s recommendations were based on shorter overall survival in the Rova-T arm, compared with the topotecan control arm, the company said.
AbbVie acquired Rova-T through its $5.8 billion acquisition of Stemcentrx in 2016, as the company aimed to enter the broad and lucrative arena of solid tumours and lessen dependence on its arthritis treatment Humira, the world’s top-selling drug.
In March, AbbVie had said it would not seek accelerated approval for the drug, in a setback to the company’s efforts to build its cancer drug pipeline.
Rova-T is a toxic chemical that is loaded onto an antibody to target a protein called DLL3 found in more than 80 per cent of patients with cancer. A biomarker is used to help select patients whose cancers express the protein.